IQVIA (IQV) vs Natera (NTRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Natera (NTRA) has outperformed IQVIA (IQV) over the past year, gaining 127.1% versus a gain of 29.1%. Over five years, NTRA leads with a +252.8% price change compared with +4.0% for IQV. Natera is the larger company by market cap ($57.75 billion vs $43.07 billion), about 1.3 times the size.
IQVIA converts more of its revenue into profit, with a net margin of 8.3% versus -9.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IQV | NTRA |
|---|---|---|
| Share price | $261.69 | $400.63 |
| Market cap | $43.07B | $57.75B |
| 1-day change | +1.08% | +2.52% |
| YTD return | +14.85% | +70.58% |
| 1-year return | +29.05% | +127.08% |
| 5-year return | +4.03% | +252.79% |
| P/E ratio (TTM) | 32.51 | — |
| Forward P/E | 18.13 | — |
| EPS (TTM) | $8.05 | $-1.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $16.31B | $2.31B |
| Revenue growth (YoY) | +5.87% | +35.90% |
| Net income (latest FY) | $1.36B | $-208.16M |
| Gross margin | 33.29% | — |
| Operating margin | 13.38% | -13.44% |
| Net margin | 8.34% | -9.03% |
| 52-week high | $277.40 | $437.41 |
| 52-week low | $154.50 | $167.99 |
| Distance from 52-week high | -5.67% | -8.41% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +11.14% | -5.79% |
| Average volume | 1.45M | 1.45M |
| Shares outstanding | 164.60M | 144.14M |
| Employees | 94,000 | 6,135 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NTRA has outperformed IQV by 98.0 percentage points over the past year.
- IQVIA is more profitable, keeping 8.3 cents of every revenue dollar as net income versus -9.0 cents for Natera.
- Natera grew revenue faster in its latest fiscal year (+35.90% vs +5.87%).
About IQVIA
IQV stock →IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 94,000 employees
About Natera
NTRA stock →Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.
Health Care · Medical Specialities · 6,135 employees
IQV vs NTRA FAQ
Which is bigger, IQVIA or Natera?
Natera (NTRA) is larger, with a market capitalization of $57.75B compared with $43.07B for IQVIA (IQV).
Which stock has performed better over the past year, IQV or NTRA?
NTRA returned +127.08% over the past 12 months, compared with +29.05% for IQV (price return, excluding dividends). Past performance does not predict future results.
Are IQVIA and Natera in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Commercial Physical & Biological Resarch for IQVIA and Medical Specialities for Natera.